Company Overview and News

9
AVEO (AVEO) Up 25.3% Since Last Earnings Report: Can It Continue?

2018-09-06 zacks - 2
A month has gone by since the last earnings report for AVEO Pharmaceuticals (AVEO - Free Report) . Shares have added about 25.3% in that time frame, outperforming the S&P 500.
AVEO KHC PE

9
Aveo Stock Breaks Out After Strong Drug Results and a Modest Offering

2018-08-30 investorplace - 6
When a biotech company prices a common stock offering, diluting existing shareholders, the stock typically falls. Yet when AVEO Pharmaceuticals (NASDAQ:AVEO) announced a $5.7 million share offering on Aug. 17, the stock went the other way. It’s rallied from $2.29 to $2.90, a 27.5% rally. So why are markets buying AVEO stock?
AVEO

3
AVEO / AVEO Pharmaceuticals, Inc. null

2018-08-23 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C<@,"!O8FH-/#PO3&EN96%R:7IE9" [email protected],S$Y M-C4O3R [email protected],C
AVEO

7
AVEO / AVEO Pharmaceuticals, Inc. null

2018-08-23 sec.gov - 4
CORRESP AVEO Pharmaceuticals, Inc. One Broadway, 14th Floor Cambridge, Massachusetts 02142 July 23, 2018
AVEO

13
Your Cancer Highlight: The Study That Could Bridge The New Key Competitors In Kidney Cancer

2018-08-23 seekingalpha - 8
By joining forces, Bristol-Myers and Exelixis are offering a synergistic approach to kidney cancer that may end up being the first-line standard of care.
EXEL AVEO NVS PFE

21
Week In Review: Shanghai ChemPartner, A China CRO/CMO, Completes Reverse Merger

2018-08-19 seekingalpha - 4
Shanghai ChemPartner, a CRO/CMO, closed its reverse merger with Quantum Hi-Tech China Biological (SZE:300149) for a combination of cash and stock. ChemPartner said it will have easier access to additional capital as a listed entity. Quantum makes probiotics for packaged foods, and its operations will remain separate from ChemPartner's. The merger was first announced over a year ago, though terms of the agreement have not been disclosed.
BGX AVEO BX BGLF CHNA WXXWY BGB

3
AVEO / AVEO Pharmaceuticals, Inc. 424B5 (Prospectus)

2018-08-17 sec.gov
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-221837 Prospectus Supplement (To Prospectus dated Dece
AVEO

3
AVEO / AVEO Pharmaceuticals, Inc. FORM 8-K (Current Report)

2018-08-17 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AVEO

3
AVEO / AVEO Pharmaceuticals, Inc. 424B5 (Prospectus)

2018-08-17 sec.gov
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-221837 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective b
AVEO

110
Top Analyst Upgrades and Downgrades: AVEO, Boeing, Canopy Growth, Coty, Kimberly-Clark, Lululemon, Macy’s, Sysco, Teladoc and More

2018-08-16 247wallst - 8
Stocks were indicated to open handily higher after strong Walmart earnings and after reports that China is engaging in new trade talks. Earnings season is now about 85% over, and it has been quite strong with over 70% of the companies exceeding expectations. That said, the stock market volatility in 2018 has created less rewarding trades by buying the dips, which had been so reliable in prior years.
SYY STZ.B GSKY CONN STZ KMB CGC ERJ AVLR TWMJF HIMX AVEO BOE WEED TRI MS BA COTY

3
AVEO / AVEO Pharmaceuticals, Inc. 8-K (Current Report)

2018-08-14 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
AVEO

7
AVEO Pharmaceuticals (AVEO) Q2 Loss In Line, Revenues Miss

2018-08-08 zacks - 2
AVEO Pharmaceuticals, Inc. (AVEO - Free Report) reported second-quarter 2018 adjusted loss of 6 cents per share, matching the Zacks Consensus Estimate. However, the loss was narrower than the year-ago adjusted loss of 8 cents.
SGEN OAS GILD AVEO

3
AVEO / AVEO Pharmaceuticals, Inc. 10-Q (Quarterly Report)

2018-08-08 sec.gov
aveo-10q_20180630.htm UNITED STATES
AVEO

3
AVEO / AVEO Pharmaceuticals, Inc. 8-K (Current Report)

2018-08-08 sec.gov
aveo-8k_20180807.htm UNITED STATES
AVEO

42
Ziopharm Oncology Announces Changes to its Board of Directors

2018-08-07 globenewswire
BOSTON, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced changes to the Company’s Board of Directors. Scott Tarriff, a member of the Board since 2015, has been elected to serve as Lead Director, succeeding Sir Murray Brennan, M.D. Both Sir Dr. Brennan and former U.S. Sen. William Wyche Fowler will step down when their terms expire on September 18, 2018, the date of the annual meeting of shareholders.
ZIOP MKGAF EGRX XLRN XON MKGAY BIIB AVEO PRTK

AVEO : AVEO Pharmaceuticals Stock Analysis and Research Report

2017-10-02 - Asif

AVEO Pharmaceuticals is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company proprietary platform has delivered unique insights into cancer and related diseases. The company's strategy is to leverage these biomarker insights and partner resources to advance the development of its clinical pipeline. The company is focused on developing its lead candidate tivozanib in North America as a treatment for renal cell carcinoma, or RCC. In addition, The company has entered into partnerships to fund the further development and commercialization of its clinical stage assets, including AV-380, ficlatuzumab, AV-203, and tivozanib for oncology indications outside of North America. The company is currently seeking a partner to develop the AV-353 platform, a preclinical asset, worldwide for the potential treatment of pulmonary arterial hypertension, or PAH. Going Concern AVEO Pharmaceutic...

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to AVEO / AVEO Pharmaceuticals, Inc. on message board site Silicon Investor.

AVEO Pharmaceuticals AVEO Pharmaceuticals AVEO Pharmaceuticals
CUSIP: 053588109